Nurix Therapeutics CFO Houte Hans van Sells $74.6K of Stock
Houte Hans van, CFO, sold 4,769 shares of Nurix Therapeutics, Inc. at $15.38 to $16.20 a share (average $15.63) in 2 transactions, worth $74.6K in total on Nov 4, 2026. Shares held after the trade: 42,745 (-3.3%).
Nurix Therapeutics CLO Christine Ring Sells $432K of Stock
Christine Ring, CLO, sold 16,715 shares of Nurix Therapeutics, Inc. at $25.74 to $26.76 a share (average $25.84) in 3 transactions, worth $432K in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 4,406 (-58.1%).
Nurix Therapeutics Deal Termination with Sanofi S.A.
Nurix Therapeutics announced that its collaboration partner Sanofi has decided to discontinue the Phase 1 clinical trial and terminate the SAR448272 oral STAT6 degrader program. As a result, Nurix will no longer be eligible for future development, regulatory, or commercial milestone payments and royalties specifically for this program, though other licensed programs under the Sanofi collaboration remain active.
Nurix Therapeutics CFO Houte Hans van Sells $74.5K of Stock
Houte Hans van, CFO, sold 2,834 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $74.5K in total on Oct 30, 2026. Shares held after the trade: 47,514 (-5.6%).
Nurix Therapeutics CLO Christine Ring Sells $104K of Stock
Christine Ring, CLO, sold 3,957 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $104K in total on Oct 30, 2026. Shares held after the trade: 15,335 (-20.5%).
Nurix Therapeutics CSO Gwenn Hansen Sells $143K of Stock
Gwenn Hansen, CSO, sold 5,409 shares of Nurix Therapeutics, Inc. at $26.28 to $26.80 a share (average $26.42) in 2 transactions, worth $143K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 123,452 (-1.2%).
Nurix Therapeutics CSO Gwenn Hansen Sells $36.3K of Stock
Gwenn Hansen, CSO, sold 1,452 shares of Nurix Therapeutics, Inc. at $25.00 a share, worth $36.3K in total on Oct 15, 2026. Shares held after the trade: 117,227 (-1.2%).
Nurix Therapeutics Insider Julia P. Gregory Sells $529K of Stock
Julia P. Gregory sold 22,583 shares of Nurix Therapeutics, Inc. at $23.40 a share, worth $529K in total on Oct 14, 2026. Shares held after the trade: 10,750 (-67.7%).
Nurix Therapeutics reported a significant swing to profitability for the quarter ended August 31, 2026, with net income of $549.8 million compared to a net loss of $86.4 million in the prior year, primarily driven by $653.2 million in license revenue. The company's cash position strengthened significantly to $720.2 million, up from $247.0 million at the end of fiscal 2025.
Nurix Therapeutics reported financial results for its fiscal third quarter ended August 31, 2026, highlighting a cash position of $1.1 billion following a $700 million upfront payment from its Roche collaboration. The company achieved several clinical milestones, including dosing the first patient in its Phase 3 DAYBreak CLL-306 trial and advancing its STAT6 degrader into Phase 1 with Sanofi.
Term
Q3 2026
“The third quarter marked an important transition for Nurix as we moved bexobrutideg into Phase 3 development in CLL and began executing a broader clinical strategy designed to realize its potential across lines of therapy in both oncology and auto-immune disease.”
Arthur T. Sands, M.D., Ph.D., president and chief executive officer
Nurix Therapeutics CLO Christine Ring Sells $134K of Stock
Christine Ring, CLO, sold 5,786 shares of Nurix Therapeutics, Inc. at $23.19 a share, worth $134K in total on Oct 2, 2026. Shares held after the trade: 9,110 (-38.8%).